- Home
- ACM vs RPRX Comparison
ACM vs RPRX Comparison
Compare ACM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACM | RPRX |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 16.7B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACM | RPRX |
|---|---|---|
| Price | $96.90 | $40.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $134.00 | $45.75 |
| AVG Volume (30 Days) | 1.2M | ★ 3.4M |
| Earning Date | 02-09-2026 | 02-11-2026 |
| Dividend Yield | 1.28% | ★ 2.33% |
| EPS Growth | ★ 42.91 | N/A |
| EPS | ★ 4.22 | 1.75 |
| Revenue | ★ $16,139,622,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.66 |
| Revenue Next Year | $2.75 | $2.34 |
| P/E Ratio | ★ $20.27 | $23.06 |
| Revenue Growth | 0.21 | ★ 3.70 |
| 52 Week Low | $85.00 | $29.66 |
| 52 Week High | $135.52 | $41.70 |
Technical Indicators
Market Signals| Indicator | ACM | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 57.64 |
| Support Level | $94.46 | $38.86 |
| Resistance Level | $99.12 | $40.58 |
| Average True Range (ATR) | 2.55 | 0.83 |
| MACD | 0.44 | -0.02 |
| Stochastic Oscillator | 38.38 | 57.67 |
Price Performance
Historical ComparisonAbout ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.